Results 181 to 190 of about 30,994 (308)

Continued norovirus false positivity after FDA clearance of the BioFire FilmArray gastrointestinal panel. [PDF]

Microbiol Spectr
Daley M, Poulter MD, Snavely EA.
europepmc   +1 more source

MicroRNA‐Driven Regulation of β‐Cell Function in Type 2 Diabetes: Molecular Mechanisms, Network Insights, and Translational Perspectives

Acta Physiologica, Volume 242, Issue 9, September 2026.
ABSTRACT MicroRNAs (miRNAs) have emerged as central regulators of pancreatic islet biology, influencing β‐cell development, proliferation, and function. In type 2 diabetes (T2D), both adaptive and maladaptive miRNA responses shape β‐cell compensation and progressive secretory dysfunction.
Lena Eliasson, Alexandros Karagiannopoulos, Mototsugu Nagao, Anna Wendt   +3 more
wiley   +1 more source

Glucagon-like Peptide-1 and Dual GIP/GLP-1 Receptor Agonists in Brain: Exploring the Expanding Role and Safety in Neuropsychiatry. [PDF]

Int J Mol Sci
Tudosie AC, Marin LM, Popa SG, Golli AL.
europepmc   +1 more source

Dual Glucagon and GLP‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8242-8253, September 2026.
ABSTRACT Aims This post hoc analysis evaluated the effect of survodutide on beta‐cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations. Materials and Methods Trial 1404‐0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.
Elif I. Ekinci, Sandra González Maldonado, Anna Unseld, Jorge Arrubla Martinez, Anita M. Hennige, Corinna Schoelch   +5 more
wiley   +1 more source

Novel evidence for tirzepatide, a dual GLP-1/GIP receptor agonist, to reduce the motivation for cocaine in rodents. [PDF]

EBioMedicine
Knackstedt LA.
europepmc   +1 more source

Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8072-8083, September 2026.
ABSTRACT Aims Tirzepatide is a once‐weekly glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonist (RA) approved for weight management in adults with obesity. Data on older adults remain limited, however. This study aimed to examine tirzepatide's safety and efficacy in adults aged ≥ 65 years with obesity ...
Nasreen Alfaris, Robert F. Kushner, Jianghao Li, Kevin L. Chen, Mia Fenimore, Boris Calderon, Adam Stefanski   +6 more
wiley   +1 more source

Glucagon-like peptide-1 (GLP-1) levels are associated with acute kidney injury after cardiac surgery. [PDF]

Sci Rep
Szafran A, Kurt B, Pracht J, Zechendorf E, Breuer T, Stoppe C, Marx G, Tacke F, Kahles F, Mossanen JC.   +9 more
europepmc   +1 more source

Effects of Incretin‐Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat‐Free Mass in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7737-7751, September 2026.
ABSTRACT Background Maintaining fat‐free mass (FFM) during weight loss is important to maintain a healthy body composition. This review examined changes in FFM during weight loss induced by diet and exercise interventions, incretin‐based therapies, and bariatric surgery, and assessed whether the relative loss of FFM differs by weight‐loss modality ...
Laura Busk‐Cirera, Ida Ørum Carlsen, Lærke Bruun Madsen, Rasmus Michael Sandsdal, Emma Jensen, Simon Birk Kjær Jensen, Signe Sørensen Torekov   +6 more
wiley   +1 more source

Dietary intake patterns and nutritional adequacy among adults with overweight or obesity treated with GLP-1 or dual GIP/GLP-1 receptor agonists- preliminary study. [PDF]

J Transl Med
Korus S, Cembrowska-Lech D, Kłoda K, Stachowska E.   +3 more
europepmc   +1 more source

Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT‐1 and SURMOUNT‐2 Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8367-8377, September 2026.
ABSTRACT Aims Obesity affects over 800 million people globally and is associated with complications including cardiovascular disease and type 2 diabetes (T2D). Early response to weight loss interventions may help optimize achievement of individual treatment goals.
Alexander Kokkinos, Tina Thethi, Clare J. Lee, Lisa M. Neff, Adam Stefanski, Dachuang Cao, Angel Rodriguez, Amy Bartee   +7 more
wiley   +1 more source